Advances in SM

CE / CME

Advances in Systemic Mastocytosis: Getting to the Root of Disease With New and Emerging Targeted Treatments

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Released: December 16, 2024

Expiration: December 15, 2025

Matthew Giannetti
Matthew Giannetti, MD

Activity

Progress
1 2
Course Completed

References

  1. Brockow K. Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin North Am. 2014;34:283-295.
  2. Jennings SE, Russell NC, Jennings B, et al. The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions. J Allergy Clin Immunol Pract. 2014;2:70-76.
  3. Jackson CW, Pratt CM, Rupprecht CP, et al. Mastocytosis and mast cell activation disorders: clearing the air. Int J Mol Sci. 2021;22:11270.
  4. Valent P, Akin C, Bonadonna P, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin Immunol Pract. 2019;7:1125-1133.e1.
  5. Weiler CR. Mast cell activation syndrome: tools for diagnosis and differential diagnosis. J Allergy Clin Immunol Pract. 2020;8:498-506.
  6. Jennings SV, Slee VM, Zack RM, et al. Patient perceptions in mast cell disorders. Immunol Allergy Clin North Am. 2018;38:505-525
  7. Boggs NA, Tanasi I, Hartmann K, et al. Mast cell disorders and hymenoptera venom-triggered anaphylaxis: evaluation and management. J Allergy Clin Immunol Pract. 2024:S2213-2198(24)00853-5. Epub online ahead of print.
  8. Hartmann K, Escribano L, Grattan C, et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016;137:35-45.
  9. Berezowska S, Flaig MJ, Franziska Ruëff, et al. Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis. Mod Path. 2014;27:19-29.
  10. Piris-Villaespesa M, Alvarez-Twose I. Systemic mastocytosis: following the tyrosine kinase inhibition roadmap. Front Pharmacol. 2020;11:443.
  11. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703-1719.
  12. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200-1228.
  13. George TI, Horny HP. Systemic mastocytosis. Hematol Oncol Clin North Am. 2011;25:1067-1083.
  14. George TI, Hoehn G, Lin H-M, et al. Increased detection of KIT D816V mutation in peripheral blood samples from patients with indolent systemic mastocytosis (ISM) in the phase 2 Pioneer study using a high sensitivity droplet digital (dd) PCR assay compared with next generation sequencing (NGS). Presented at: American Society of Hematology Annual Meeting and Exposition; December 5-8, 2020. Abstract 3004.
  15. Tzankov A, Duncavage E, Craig FE, et al. Mastocytosis. Am J Clin Pathol. 2021;155:239-266.
  16. Akin C. How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms. Hematology. 2022;2022:55-63.
  17. Lyons JJ. Inherited and acquired determinants of serum tryptase levels in humans. Ann Allergy Asthma Immunol. 2021;127:420-426.
  18. Zanotti R, Bonifacio M, Lucchini G, et al. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. Leukemia. 2022;36:516-524.
  19. Valent P, Akin C, Hartmann K, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. HemaSphere. 2021;5:e646.
  20. Lyons JJ, Chovanec J, O’Connell MP, et al. Heritable risk for severe anaphylaxis associated with increased α-tryptase–encoding germline copy number at TPSAB1. J Allergy Clin Immunol. 2021;147:622-632.
  21. Couto ML, Silva M, Barbosa MJ, et al. Defining hereditary alpha-tryptasemia as a risk/modifying factor for anaphylaxis: are we there yet? Eur Ann Allergy Clin Immunol. 2023;55:152-160.
  22. Sordi B, Vanderwert FI, Crupi F, et al. Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis. J Allergy Clin Immunol. 2023;151:485-493.e11.
  23. Giannetti MP, Weller E, Bormans C, et al. Hereditary alpha-tryptasemia in 101 patients with mast cell activation–related symptomatology including anaphylaxis. Ann Allergy Asthma Immunol. 2021;126:655-660.
  24. Escribano L, Akin C, Castells M, et al. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol. 2002;81:677-690.
  25. Butterfield JH. Increased excretion of mast cell mediator metabolites during mast cell activation syndrome. J Allergy Clin Immunol Pract. 2023;11:2542-2546.
  26. Castells M, Butterfield J. Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management. J Allergy Clin Immunol Pract. 2019;7:1097-1106.
  27. Midostaurin [prescribing information]. East Hanover, NJ: Novartis. 2023.
  28. Alvarez-Twose I, Matito A, Morgado JM, et al. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. Oncotarget. 2016;8:68950-68963.
  29. American Academy of Allergy Asthma & Immunology. A new therapy to calm down mast cells. https://www.aaaai.org/tools-for-the-public/latest-research-summaries/the-journal-of-allergy-and-clinical-immunology-in/2019/mast-cells. Accessed December 9, 2024.
  30. Castells M, Akin C. Finding the right KIT inhibitor for advanced systemic mastocytosis. Nat Med. 2021;27:2081-2082.
  31. Gotlib J, Castells M, Oude Elberink H, et al. Avapritinib versus placebo in indolent systemic mastocytosis. NEJM Evid. 2023;2:EVIDoa2200339.
  32. Padilla B, Shields AL, Taylor F, et al. Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study. Orphanet J Rare Dis. 2021;16:434.
  33. Sabato V, Gotlib J, Castells M et al. Longer-term safety of avapritinib in indolent systemic mastocytosis: the phase 2 PIONEER study. Presented at: European Academy of Allergy & Clinical Immunology Congress; May 31 - June 3, 2024.
  34. Blevins AS. Avapritinib shows durable responses in long-term follow-up in advanced systemic mastocytosis. Report from the 2023 Society of Hematologic Oncology Annual Meeting. https://www.hematologyadvisor.com/reports/mastocytosis-avapritinib-durable-response-treatment-risk/. Accessed December 2, 2024.
  35. Bose P, Oh ST, Modena B, et al. Initial results from SUMMIT: an ongoing, 3-part, multi-center, randomized, double-blind, placebo-controlled phase 2 clinical study of bezuclastinib in adult patients with nonadvanced systemic mastocytosis (NonAdvSM). Blood. 2023;142(suppl 1):77.
  36. Rein L, Modena B, Siebenhaar F, et al. Symptom-focused results from SUMMIT part 1: an ongoing, randomized, double-blind, placebo-controlled phase 2 clinical trial of bezuclastinib in adult patients with nonadvanced systemic mastocytosis. Presented at: European Hematology Association Congress; June 13-16, 2024. Abstract P1055.
  37. Alvarado D, Maurer M, Gedrich R, et al. Anti‐KIT monoclonal antibody CDX‐0159 induces profound and durable mast cell suppression in a healthy volunteer study. Allergy. 2022;77:2393-2403.
  38. D’Mello S, Finlay G, Baguley B, et al. Signaling pathways in melanogenesis. Int J Mol Sci. 2016;17:1144.
  39. Rambhatla A, Strug MR, De Paredes JG, et al. Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review. J Assist Reprod Genet. 2021;38:1897-1908.
  40. Namazy JA, Blais L, Andrews EB, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J Allergy Clin Immunol. 2020;145:528-536.e1.